Cargando…

Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer’s disease

BACKGROUND: The burden on caregivers of patients with Alzheimer’s disease (AD) is associated with the patient’s functional status and may also be influenced by chronic comorbid medical conditions, such as diabetes. This post-hoc exploratory analysis assessed whether comorbid diabetes in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebrec, Jeremie, Ascher-Svanum, Haya, Chen, Yun-Fei, Reed, Catherine, Kahle-Wrobleski, Kristin, Hake, Ann Marie, Raskin, Joel, Naderali, Ebrahim, Schuster, Dara, Heine, Robert J., Kendall, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855347/ https://www.ncbi.nlm.nih.gov/pubmed/27142529 http://dx.doi.org/10.1186/s12877-016-0264-8

Ejemplares similares

Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study
por: Reed, Catherine, et al.
Publicado: (2018)

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis
por: Ascher-Svanum, Haya, et al.
Publicado: (2015)

Erratum to: Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis
por: Ascher-Svanum, Haya, et al.
Publicado: (2015)

Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes
por: Jones, Roy W., et al.
Publicado: (2017)

Detection, diagnosis, and treatment of Alzheimer’s disease dementia stratified by severity as reported by caregivers in Japan
por: Montgomery, William, et al.
Publicado: (2018)

Assessing quality of life in Alzheimer's disease: Implications for clinical trials
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2016)

Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

Alzheimer’s disease severity and its association with patient and caregiver quality of life in Japan: results of a community-based survey
por: Montgomery, William, et al.
Publicado: (2018)

Impact of caring for persons with Alzheimer’s disease or dementia on caregivers’ health outcomes: findings from a community based survey in Japan
por: Goren, Amir, et al.
Publicado: (2016)

Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2014)

The influence of caregivers and behavioral and psychological symptoms on nursing home placement of persons with Alzheimer’s disease: A matched case–control study
por: Porter, Candace N, et al.
Publicado: (2016)

Modeling the course of Alzheimer's disease to improve clinical trials: symposium report
por: Spiegel, René, et al.
Publicado: (2013)

Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
por: Kirson, Noam Y., et al.
Publicado: (2016)

The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy
por: Montgomery, William, et al.
Publicado: (2013)

Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use: an analysis of the NACC-UDS database
por: Gaugler, Joseph E, et al.
Publicado: (2013)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Understanding the Complexities of Functional Ability in Alzheimer’s Disease: More Than Just Basic and Instrumental Factors
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2014)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
por: Faries, Douglas E, et al.
Publicado: (2009)

Using U.S. Medicare records to evaluate the indirect health effects on spouses: a case study in Alzheimer’s disease patients
por: Gilden, Daniel M, et al.
Publicado: (2014)

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2004)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model
por: Furiak, Nicolas M, et al.
Publicado: (2010)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
por: Stauffer, Virginia, et al.
Publicado: (2009)

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
por: Montgomery, William, et al.
Publicado: (2012)

Describing the Sequence of Cognitive Decline in Alzheimer’s Disease Patients: Results from an Observational Study
por: Henneges, Carsten, et al.
Publicado: (2016)

Item response analysis of the Positive and Negative Syndrome Scale
por: Santor, Darcy A, et al.
Publicado: (2007)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Schizophrenia Outpatient Health Outcomes study: twelve-month findings
por: Novick, Diego, et al.
Publicado: (2012)

Caregiver burden and coping strategies in caregivers of patients with Alzheimer’s disease
por: Iavarone, Alessandro, et al.
Publicado: (2014)

Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study
por: Lenox-Smith, Alan, et al.
Publicado: (2016)

How to deal with missing longitudinal data in cost of illness analysis in Alzheimer’s disease—suggestions from the GERAS observational study
por: Belger, Mark, et al.
Publicado: (2016)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
por: Peng, Xiaomei, et al.
Publicado: (2011)

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
por: Cuyún Carter, Gebra B, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0lgd9b5lkf4lj9voou52q0h09a